A new research review published in Current Asthma & Allergy Reports highlights how mast cell mediators may help improve the way mast cell activation disorders, including systemic mastocytosis (SM), are identified and monitored.
Mediators are chemical substances released by mast cells during activation, triggering symptoms such as flushing, itching, gastrointestinal issues and in some cases anaphylaxis. While many mediators exist, only a handful are clinically useful as biomarkers to help clinicians diagnose mast cell disorders. These include tryptase, histamine metabolites, prostaglandin metabolites and leukotriene metabolites.
Serum tryptase is the gold standard for diagnosing SM, as elevated levels often reflect a higher mast cell burden. The marker is also widely used to monitor disease activity and response to treatment.
However, the review emphasizes that tryptase alone is not always sufficient. Levels can vary significantly between individuals and may be elevated in a small portion of the general population due to hereditary traits. In addition, tryptase may not fully capture all forms of mast cell activation, particularly in cases with more localized symptoms.
Urinary markers, such as metabolites of histamine, prostaglandins and leukotrienes, are increasingly recognized as valuable complementary tools. While not part of formal diagnostic criteria for SM, elevated levels can support the diagnosis and help guide further testing, such as bone marrow biopsy, the researchers note.
Learn more about SM testing and diagnosis
These markers may also be useful for distinguishing between clonal conditions like SM and nonclonal mast cell activation disorders, which include many allergic diseases.
Overall, the study’s authors say that findings underscore the expanding role of mast cell mediators in both diagnosing and managing disease. A better understanding of how and when to measure these biomarkers could lead to more accurate diagnoses and improved care for patients with mast cell-related conditions.
“Despite the advancements in understanding mast cell mediators, there is a need for further research to develop more precise biomarkers and therapeutic strategies,” the researchers conclude. “By enhancing our knowledge of mast cell biology and its clinical implications, we can better manage and treat patients with mast cell activation disorders.”
Sign up here to get the latest news, perspectives, and information about SM sent directly to your inbox. Registration is free and only takes a minute.
